Citations

Clear

401 citation(s) found for "Camilleri, M".

S1232 Patterns of Abnormal MUC1 Expression in Patients With Pouchitis
Nakhleh, Raouf E. , Camilleri, Michael , Kurdi, Ahmed T. , Faubion, William A. , Leighton, Jonathan A. , Raffals, Laura E., Francis, Fadi, Hashash, Jana G. , Yan, Irene K. , Patel, Tushar , Raffals, Laura E. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S877-S877

10.14309/01.ajg.0001034296.75121.1b Get It

S1233 Comparative Effectiveness of Bile Acid Sequestrants and Antibiotics in the Management of Pouchitis: A Matched Cohort Study From the United States
Camilleri, M., Massad, Abdulla, Alsakarneh, Saqr , Farraye, Francis A. , Hashash, Jana G.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S878-S878

10.14309/01.ajg.0001034300.46088.05 Get It

S801 Dose-Related Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function
Lupianez‐Merly, Camille , Busciglio, Irene, Eckert, Deborah J., Ryks, Michael, Dyer, Roy B. , Vizenor, Brady A., Zhao, Yuxi , Sapone, Anna, Rooks, Michelle, Gale, Jeremy D. , Camilleri, Michael , Yang, David Yi , Jencks, Kara J. , Dilmaghani, Saam , Vizenor, Brady A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S552-S553

10.14309/01.ajg.0001032572.47643.cf Get It

Intestinal Barrier Impairment, Preservation, and Repair: An Update
Matar, Ayah , Damianos, John , Jencks, Kara J. , Camilleri, Michael , Matar, Ayah , Damianos, John A , Jencks, Kara , Matar, Ayah

Mayo Clinic

Nutrients | October 15, 2024 | Volume: 16 | Issue: 20 | Pages: 3494

10.3390/nu16203494 | PMID 39458489 Get It

Background/Objectives: Our objective was to review published studies of the intestinal barrier and permeability, the deleterious effects of dietary components (particularly fat), the impact of altered intestinal permeability in disease models and human diseases, the role of the microbiome and epigenomics in control of barrier function, and the opportunities to restore normal barrier function with dietary interventions and products of the microbiota. Methods: We conducted a literature review including the following keywords alone or in combination: intestinal barrier, permeability, microbiome, epigenomics, diet, irritable bowel syndrome, inflammatory bowel disease, probiotics. Results: Intestinal permeability is modified by a diet including fat, which increases permeability, and nutrients such as fiber, glutamine, zinc, vitamin D, polyphenols, emulsifiers, and anthocyanins, which decrease permeability. There is significant interaction of the microbiome and barrier function, including the inflammatory of luminal/bacterial antigens, and anti-inflammatory effects of commensals or probiotics and their products, including short-chain fatty acids. Epigenomic modification of barrier functions are best illustrated by effects on junction proteins or inflammation. Detailed documentation of the protective effects of diet, probiotics, prebiotics, and microbiota is provided. Conclusion: intestinal permeability is a critical factor in protection against gastrointestinal diseases and is impacted by nutrients that preserve or heal and repair the barrier and nurture anti-inflammatory effects.
LAPONITE® nano-silicates potentiate the angiogenic effects of FG-4592 and osteogenic effects of BMP-2
Gaihre, Bipin , Tilton, Maryam , Potes, Maria Astudillo , Liu, Xifeng , Camilleri, Emily , Astudillo Potes, Maria D, Liu, Xifeng , Lucien, Fabrice , Tilton, Maryam , Camilleri, Emily T. , Lucien, Fabrice , Lu, Lichun

Mayo Clinic

Biomaterials Science | September 24, 2024 | Volume: 12 | Issue: 21 | Pages: 5610-5619

10.1039/d4bm00636d | PMID 39359127 Get It

LAPONITE®-based drug delivery systems for the delivery of drugs and biomolecules with high biological potentiation and synergy.
Additional criteria on scintigraphic testing for diagnosis of rapid colonic transit in patients with chronic diarrhea
Lupianez‐Merly, Camille , Dilmaghani, Saam , Jencks, Kara J. , Eckert, Deborah J., Ryks, Michael, Burton, Duane, Camilleri, Michael , Jencks, Kara , Eckert, Deborah

Mayo Clinic

Neurogastroenterology & Motility | September 20, 2024 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/nmo.14917 | PMID 39300973 Get It

AbstractBackgroundColonic transit (CT) measured by validated scintigraphy using 111In‐labeled activated charcoal particles is summarized using geometric center (GC) of isotopic distribution in four colonic regions and stool at 24 and 48 h. Diagnosis of rapid CT is currently based on GC24 ≥4.4 in females and >4.7 in males, which lack sensitivity. Our aim was to evaluate, in patients with chronic diarrhea with normal CT by GC24 and GC48, the diagnostic utility of CT change (∆GC) relative to sex‐matched normal values.MethodsWe evaluated two adult patient cohorts: 701 clinical patients (1994–2023) with chronic diarrhea and 76 research participants with irritable bowel syndrome with diarrhea (N = 63) or bile acid diarrhea (BAD, N = 13). Results of ∆GC were compared to 220 healthy controls' 95th percentiles (%ile) (≥2.0 females and ≥2.2 males). In the research cohort, we also analyzed (Spearman correlation) colonic ∆GC with ascending colon emptying T1/2 (AC T1/2), average stool frequency and consistency based on a daily diary, total fecal bile acid (BA) concentration, and % primary BA in a single stool sample.Key ResultsAmong 701 clinical patients with normal GC24, 160 (22.3%) had rapid CT based on ∆GC 95th %ile in health. Among 76 research participants, an additional 20.6% IBS‐D and 23% BAD had rapid CT ∆GC. Younger age and absence of diabetes mellitus were predictive of rapid ∆GC. ∆GC significantly correlated with AC T1/2 and with fecal BA.Conclusions & Inferences∆GC identified an additional 21%–23% patients with rapid colonic transit among patients with diarrhea and normal GC24.
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?
Camilleri, Michael

Mayo Clinic

Gut | August 17, 2024 | Volume: 74 | Issue: 3 | Pages: 342-345

10.1136/gutjnl-2024-333036 | PMID 39153846 Get It

Comparison of Digital Pathology and Light Microscopy Among Dermatology Residents: A Reappraisal Following Practice Changes
Neal, Donald, Johnson, Emma F. , Agrawal, Shruti , Camilleri, Michael , Wieland, Carilyn N. , Neal, Donald E, Todd, Austin W.

Mayo Clinic

The American Journal of Dermatopathology | August 14, 2024 | Volume: 47 | Issue: 1 | Pages: 25-29

10.1097/dad.0000000000002805 | PMID 39141713 Get It

Background: Following transition to digital pathology for primary diagnosis at our institution, dermatology residents have reduced exposure to light microscopy. This study compares resident competency with light microscopy versus digital pathology following practice changes. Methods: Twenty-one dermatology residents were administered a dermatopathology examination composed of 32 diagnoses evaluated using digital slides and 32 with light microscopy. Case difficulty was graded and balanced between modalities. Diagnostic accuracy was measured using the number of correct diagnoses for each modality. Participants were surveyed regarding their experience and preferences. Results: Diagnostic accuracy was higher with digital pathology than light microscopy (22/32 vs. 18/32, P < 0.001). Diagnostic accuracy with digital pathology increased with years of training, but accuracy with light microscopy did not. Residents with previous light microscopy experience achieved an average score of 19/32 on glass, as compared with 10/32 for those without experience (P = 0.039). Digital pathology was preferred over light microscopy (18/21, 85.7%). Conclusions: Trainees had better diagnostic proficiency with digital pathology and preferred this modality. Most practices at this time continue to use light microscopy. Therefore, we need to maintain proficiency in microscopy during training while concurrently preparing trainees for a digital future.
Interview: Michael Camilleri
Camilleri, Michael

Mayo Clinic

EMJ Gastroenterology | August 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjgastroenterol/xwyq1015 Get It

Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS‐BAD
Lupianez‐Merly, Camille , Jencks, Kara J. , Ferber, Monique, Melo, Luma , Klinken, B. Jan‐Willem van , Kalgaonkar, Swati, Camilleri, Michael , Jencks, Kara , Dilmaghani, Saam , Camilleri, M , Ferber, Monique

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 19, 2024 | Volume: 60 | Issue: 4 | Pages: 544-545

10.1111/apt.18164 | PMID 39031892 Get It